These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 6263470

  • 1. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F, Casazza AM, Di Marco A, Savi G.
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ, Cysyk RL, Kline I, Gang M, Venditti JM.
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [Abstract] [Full Text] [Related]

  • 3. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
    Baba H, Stephens LC, Strebel FR, Siddik ZH, Newman RA, Ohno S, Bull JM.
    Cancer Res; 1991 Jul 01; 51(13):3568-77. PubMed ID: 1905199
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.
    Poster DS, Penta J, Marsoni S, Bruno S, Macdonald JS.
    Cancer Clin Trials; 1980 Jul 01; 3(4):315-20. PubMed ID: 7000389
    [Abstract] [Full Text] [Related]

  • 6. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P, Gross J, Green MD.
    Cancer Res; 1990 Aug 15; 50(16):5136-42. PubMed ID: 2116226
    [Abstract] [Full Text] [Related]

  • 7. Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters.
    Herman EH, El-Hage AN, Ferrans VJ, Witiak DT.
    Res Commun Chem Pathol Pharmacol; 1983 May 15; 40(2):217-31. PubMed ID: 6410471
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL, Roberts BJ, Howard CT, Leopold WR.
    Cancer Res; 1994 Aug 15; 54(16):4412-8. PubMed ID: 8044790
    [Abstract] [Full Text] [Related]

  • 10. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line.
    Wadler S, Green MD, Muggia FM.
    Cancer Res; 1986 Mar 15; 46(3):1176-81. PubMed ID: 3080237
    [Abstract] [Full Text] [Related]

  • 11. [Antitumor activity of doxorubicin in the treatment of hemocytoblastosis La and various ascites tumors in mice].
    Ul'ianova LA, Tarasova VE, Bazhanov VS, Iudina OI, Gol'dberg LE.
    Antibiotiki; 1984 Nov 15; 29(11):861-6. PubMed ID: 6524889
    [Abstract] [Full Text] [Related]

  • 12. Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineoplastic agent ICRF-187.
    El-Hage AN, Herman EH, Ferrans VJ.
    Res Commun Chem Pathol Pharmacol; 1981 Sep 15; 33(3):509-23. PubMed ID: 7036302
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ.
    Cancer Chemother Rep 2; 1974 Mar 15; 4(1):45-52. PubMed ID: 4826499
    [No Abstract] [Full Text] [Related]

  • 14. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [Abstract] [Full Text] [Related]

  • 15. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K.
    Clin Cancer Res; 1999 Jul 01; 5(7):1905-17. PubMed ID: 10430098
    [Abstract] [Full Text] [Related]

  • 16. ICRF-187 in clinical oncology.
    Poster DS, Penta JS, Bruno S, Macdonald JS.
    Cancer Clin Trials; 1981 Jul 01; 4(2):143-6. PubMed ID: 6788388
    [Abstract] [Full Text] [Related]

  • 17. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B, Sehested M, Jensen PB.
    Clin Cancer Res; 1998 Jun 01; 4(6):1367-73. PubMed ID: 9626452
    [Abstract] [Full Text] [Related]

  • 18. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B, Jensen PB, Sehested M.
    Cancer Chemother Pharmacol; 1996 Jun 01; 38(3):203-9. PubMed ID: 8646793
    [Abstract] [Full Text] [Related]

  • 19. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA, Venditti JM.
    Cancer Res; 1976 Feb 01; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [Abstract] [Full Text] [Related]

  • 20. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
    Yoshida M, Maehara Y, Sugimachi K.
    Clin Cancer Res; 1999 Dec 01; 5(12):4295-300. PubMed ID: 10632373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.